ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,180.74
1.03%
US Tech 100
17,587.20
-0.13%
다우존스 지수
38,852.27
0.46%
Bitcoin
64,112.06
1.50%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Iterum Therapeutics PLC (ITRM)

  7. Iterum Therapeutics PLC (ITRM) 뉴스

ITRM

Iterum Therapeutics (ITRM)

Iterum Therapeutics PLC
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ITRM
일자시간출처헤드라인심볼기업
2024/05/0621:00GlobeNewswire Inc.Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024NASDAQ:ITRMIterum Therapeutics PLC
2024/04/2921:00GlobeNewswire Inc.Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemNASDAQ:ITRMIterum Therapeutics PLC
2024/03/2820:42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ITRMIterum Therapeutics PLC
2024/03/2820:00GlobeNewswire Inc.Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
2024/03/2205:30GlobeNewswire Inc.Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024NASDAQ:ITRMIterum Therapeutics PLC
2024/03/1521:00GlobeNewswire Inc.Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside ChatNASDAQ:ITRMIterum Therapeutics PLC
2024/03/0622:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
2024/03/0622:00GlobeNewswire Inc.Iterum Therapeutics Provides Business UpdateNASDAQ:ITRMIterum Therapeutics PLC
2024/01/3107:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
2024/01/3021:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
2024/01/3021:00PR Newswire (US)Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
2023/12/3006:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
2023/12/1421:45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
2023/12/1421:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
2023/12/0507:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ITRMIterum Therapeutics PLC
2023/12/0507:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITRMIterum Therapeutics PLC
2023/12/0422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
2023/12/0422:00GlobeNewswire Inc.Iterum Therapeutics Regains Compliance with Nasdaq Bid Price RuleNASDAQ:ITRMIterum Therapeutics PLC
2023/11/0722:30GlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:ITRMIterum Therapeutics PLC
2023/10/2422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
2023/10/2421:00GlobeNewswire Inc.Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
2023/10/1222:15GlobeNewswire Inc.Iterum Therapeutics to Present Data at IDWeek 2023NASDAQ:ITRMIterum Therapeutics PLC
2023/08/1120:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
2023/08/1120:00GlobeNewswire Inc.Iterum Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
2023/08/0506:00GlobeNewswire Inc.Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023NASDAQ:ITRMIterum Therapeutics PLC
2023/08/0205:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
2023/07/1320:07Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
2023/07/0622:25Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
2023/07/0622:24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
2023/06/1606:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ITRMIterum Therapeutics PLC
 검색 관련기사 보기:NASDAQ:ITRM

최근 히스토리

USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
NKE
Nike
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
NASDAQ
AAPL
Apple
SPI
SP500
S&P 500
USOTC
RHHBY
Roche (QX)
AMEX
XLE
Energy Select Sector SPDR
NYSE
AXP
American Express
NASDAQ
NVDA
NVIDIA
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
GOOGL
Alphabet
FX
USDGBP
US Dollar vs Sterling
NYSE
BAC
Bank of America
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유